Edwards Lifesciences Corp
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in millions, except per share information; unaudited)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net sales | $1,715.5 | $1,553.1 | $5,105.1 | $4,498.0 |
| Cost of sales | 369.2 | 345.2 | 1,124.2 | 991.2 |
| Gross profit | 1,346.3 | 1,207.9 | 3,980.9 | 3,506.8 |
| Selling, general, and administrative expenses | 560.9 | 514.6 | 1,644.3 | 1,482.3 |
| Research and development expenses | 281.4 | 280.7 | 823.6 | 811.5 |
| Certain litigation (insurance recovery) expenses, net | (12.7) | 90.4 | 30.7 | 116.8 |
| Change in fair value of contingent consideration liabilities | — | (12.5) | — | (12.5) |
| Restructuring charges, separation costs, and other (Note 3) | 10.7 | 0.1 | 10.7 | 8.5 |
| Impairment of intangible and long-lived assets (Note 2) | 220.2 | 40.0 | 220.2 | 40.0 |
| Other operating income | (13.3) | (12.5) | (38.5) | (52.9) |
| Operating income, net | 299.1 | 307.1 | 1,289.9 | 1,113.1 |
| Interest income, net | (36.5) | (38.6) | (100.0) | (112.5) |
| Loss on impairment (Note 6) | — | — | 163.6 | 47.1 |
| Other non-operating income, net (Note 7) | (27.6) | (2.7) | (115.7) | (4.0) |
| Income from continuing operations before provision for income taxes | 363.2 | 348.4 | 1,342.0 | 1,182.5 |
| Provision for income taxes | 61.8 | 56.1 | 418.5 | 190.7 |
| Net income from continuing operations | 301.4 | 292.3 | 923.5 | 991.8 |
| Loss from discontinued operations, net of tax | — | (2.0) | — | (13.6) |
| Net income | 301.4 | 290.3 | 923.5 | 978.2 |
| Less: Net loss attributable to noncontrolling interest | (6.1) | (0.8) | (6.6) | (4.1) |
| Net income attributable to Edwards Lifesciences Corporation | $307.5 | $291.1 | $930.1 | $982.3 |
| Share information (Note 14) | ||||
| Earnings (loss) per share: | ||||
| Basic | ||||
| Continuing operations | $0.53 | $0.50 | $1.61 | $1.70 |
| Discontinued operations | $— | $— | $— | $(0.02) |
| Basic earnings per share | $0.53 | $0.50 | $1.61 | $1.68 |
| Diluted | ||||
| Continuing operations | $0.53 | $0.50 | $1.61 | $1.70 |
| Discontinued operations | $— | $— | $— | $(0.03) |
| Diluted earnings per share | $0.53 | $0.50 | $1.61 | $1.67 |
| Weighted-average number of common shares outstanding: | ||||
| Basic | 576.3 | 584.7 | 577.3 | 586.2 |
| Diluted | 577.6 | 585.7 | 578.6 | 587.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.